BCR-ABL Qualitative
RT-PCR Kit - Major, Minor & Micro
BCR-ABL Qualitative RT-PCR Kit is a multiplex, TaqMan probe based qualitative assay for the specific detection of Major BCR-ABL (M-BCR), Minor BCR-ABL (m-BCR), and Micro BCR-ABL (μ-BCR) transcripts in human blood or bone marrow aspirate samples. This kit reagents enables the detection of all three BCR-ABL transcripts and ABL1 transcript (internal control) in a single tube with RNA/cDNA as a template.
SKU
-
100 Rxns : NDXIVD001
-
50 Rxns : NDXIVD001_01
-
20 Rxns : NDXIVD001_02
CDSCO
Approved
Features & Benefits:
-
Single-Tube, Multiplex Real-Time PCR Assay for sensitive and specific detection of Major (M-BCR) p210, Minor (m-BCR) p190, and Micro (μ-BCR) p230 BCR-ABL transcripts.
-
High-Quality Takara MasterMix shows Increased Inhibitor Tolerance, Thermostability, and Reproducibility.
-
The kit supports reverse transcription. No additional cDNA steps are required.
-
Turnaround Time: Within 90 Minutes
-
Works with RNA extracted from Whole Blood EDTA and Bone Marrow Aspirates
-
Compatible with FAM, HEX/VIC, Texas Red/ROX, and Cy5 supporting PCR Instruments
Storage & Precautions
-
Recommended Storage: -20°C
-
For Professional Use only.
-
Read user manual
Clinical Relevance
The BCR-ABL fusion gene results from the reciprocal translocation t(9;22)(q34;q11), known as the Philadelphia chromosome, leading to constitutive tyrosine kinase activity that plays a central role in leukemogenesis. The major BCR-ABL transcript (p210; e13a2/e14a2) is most commonly associated with Chronic Myeloid Leukemia (CML) and is also detected in a subset of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), supporting disease diagnosis and molecular classification. The minor BCR-ABL transcript (p190; e1a2) is predominantly observed in Ph+ ALL and is rarely present in CML, aiding in differential diagnosis between leukemia subtypes.
The micro BCR-ABL transcript (p230; e19a2) is infrequently detected and is typically associated with atypical or indolent myeloproliferative disorders, including CML variants with chronic neutrophilic features. Qualitative detection of major, minor, and micro BCR-ABL transcripts provides clinically relevant information for the confirmation and classification of Philadelphia chromosome–positive leukemias, supports appropriate therapeutic decision-making, particularly for tyrosine kinase inhibitor–based therapy, and establishes a baseline molecular profile for further disease monitoring using quantitative assays.
